The CAR-T Therapy Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
Adoption of CAR-T Cell Therapy in Emerging Markets Driving Market Growth
Compared to developed economies, the adoption of CAR-T cell therapy in emerging markets has been somewhat sluggish. This is mostly because these therapies come with hefty costs, and it cannot be easy to set up the required infrastructure and expertise. However, in the upcoming years, a number of variables may contribute to the growing use of CAR-T cell therapy in emerging countries. Aging populations, urbanization, and the adoption of unhealthy lifestyles are all contributing to a notable increase in cancer incidence in several emerging economies, including China, India, and Brazil. Advanced cancer therapies, such as CAR-T cell therapies, are becoming more and more necessary due to the growing burden of disease.
In emerging countries, biopharmaceutical companies are collaborating and forming partnerships with local companies and institutes to expedite the development, production, and distribution of CAR-T cell treatments. These partnerships can assist in resolving administrative and legal issues. In order to expedite the research and approval of CAR-T cell treatments, several emerging markets, like China and India, have put in place regulatory frameworks and guidelines. This could lead to increased investment and uptake.
Biopharmaceutical companies are stepping up their efforts in 2023 to leverage collaborations and strategic investments to boost the uptake of CAR-T cell treatments in emerging regions. The following are some noteworthy advancements and business expenditures in this field, particularly for 2023.
- Novartis announced plans to build a production facility for CAR-T cell treatment in Singapore at the beginning of 2023. This plant will cater to the Asia-Pacific region, which includes developing markets such as China and India. To further research and market CAR-T cell therapies in China, the business increased its partnership with Guangzhou Bio-Ree Cell Therapy Co., Ltd.
- Gilead Sciences and IndiaBioScience, an Indian biotechnology business, formed a strategic alliance in March 2023 to research and produce CAR-T cell treatments for the Indian market. The partnership intends to use Gilead’s CAR-T cell therapy technology and IndiaBioScience’s experience in cell therapy manufacturing to provide these medicines to patients in India.
- In early 2023, Bristol Myers Squibb announced plans to open a CAR-T cell therapy production facility in China, working with regional businesses. Additionally, it has been claimed that the company is in talks to introduce its CAR-T cell therapies to regulatory bodies in Brazil and other Latin American countries.
- Janssen announced in February 2023 that it will be extending its partnership with Nanjing Legend Biotech to include possible new targets and indications for the development and commercialization of CAR-T cell treatments in China. The business is also looking into joint ventures with regional businesses and organizations in other developing nations, such as Russia and India.
- In early 2023, Poseida Therapeutics (China) reported encouraging preliminary results from its Phase 1 trial assessing P-BCMA-ALLO1, a candidate for allogeneic CAR-T cell treatment, in patients with relapsed or refractory multiple myeloma.
- Chinese biopharmaceutical startup Cellular Biomedicine Group is developing autologous CAR-T cell treatment candidates for different cancer types in China, with hopes to start pivotal studies in 2023.
The investments above and collaborations underscore the increasing acknowledgment of the possibilities of CAR-T cell therapies in developing economies and the endeavours of biopharmaceutical corporations to get a foothold in these areas. Through creating manufacturing facilities, utilizing local expertise, and managing regulatory procedures, these firms seek to expand patients’ access to these cutting-edge cancer medicines in developing economies.
What Questions Should You Ask before Buying a Market Research Report?
- How is the CAR-T therapy market evolving?
- What is driving and restraining the CAR-T therapy market?
- How will each CAR-T therapy submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?
- How will the market shares for each CAR-T therapy submarket develop from 2024 to 2034?
- What will be the main driver for the overall market from 2024 to 2034?
- Will leading CAR-T therapy markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
- How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?
- Who are the leading players and what are their prospects over the forecast period?
- What are the CAR-T therapy projects for these leading companies?
- How will the industry evolve during the period between 2024 and 2034? What are the implications of CAR-T therapy projects taking place now and over the next 10 years?
- Is there a greater need for product commercialisation to further scale the CAR-T therapy market?
- Where is the CAR-T therapy market heading and how can you ensure you are at the forefront of the market?
- What are the best investment options for new product and service lines?
- What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the CAR-T Therapy market today, and over the next 10 years:
- Our 337-page report provides 117 tables and 192 charts/graphs exclusively to you.
- The report highlights key lucrative areas in the industry so you can target them – NOW.
- It contains in-depth analysis of global, regional and national sales and growth.
- It highlights for you the key successful trends, changes and revenue projections made by your competitors.
Forecasts to 2034 and other analyses reveal commercial prospects
- In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.
- You will find original analyses, with business outlooks and developments.
- Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising CAR-T Therapy prices and recent developments.
Segments Covered in the Report
Indication
- Diffuse Large B-Cell Lymphoma (DLBCL)
- Acute Lymphoblastic Leukaemia (ALL)
- Follicular Lymphoma
- Multiple Myeloma (MM)
- Others
Type
- Abecma
- Yescarta
- Kymriah
- Tecartus
- Others
Target Antigens
End-users
- Hospitals
- Specialty Clinics
- Other End-users
Patient
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and U.S., China, Brazil, and Singapore leading national markets:
North America
Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- Singapore
- Australia
- South Korea
- Rest of Asia Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
MEA
Need industry data? Please contact us today.
The report also includes profiles for some of the leading companies in the CAR-T Therapy Market, 2024 to 2034, with a focus on this segment of these companies’ operations.
Leading companies profiled in the report
- 2seventy bio, Inc.
- AbbVie Inc.
- Amgen Inc.
- Autolus Therapeutics
- BioNTech S.E.
- Bluebird bio Inc.
- Bristol-Myers Squibb
- Caribou Biosciences, Inc.
- CARsgen Therapeutics Holdings Limited
- Gilead Sciences Inc.
- GSK plc
- Intellia Therapeutics
- Johnson & Johnson Services, Inc.
- Novartis AG
- Pfizer Inc.
Overall world revenue for CAR-T Therapy Market, 2024 to 2034 in terms of value the market will surpass US$1,480 million in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How will the CAR-T Therapy Market, 2024 to 2034 report help you?
In summary, our 330+ page report provides you with the following knowledge:
- Revenue forecasts to 2034 for CAR-T Therapy Market, 2024 to 2034, with forecasts for indication, type, target antigens, end-users and patient, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.
- Revenue forecasts to 2034 for five regional and 20 key national markets – See forecasts for the CAR-T Therapy Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, Singapore, Japan, and Australia, among other prominent economies.
- Prospects for established firms and those seeking to enter the market – including company profiles for are Gilead Sciences Inc., Novartis AG, Bristol-Myers Squibb, Johnson & Johnson Services, Inc., AbbVie Inc., Amgen Inc., BioNTech S.E., Bluebird bio Inc., Caribou Biosciences, Inc., GSK plc, CARsgen Therapeutics Holdings Limited, Pfizer Inc., Autolus Therapeutics, Intellia Therapeutics, and 2seventy bio, Inc. of the major companies involved in the CAR-T Therapy Market, 2024 to 2034.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the CAR-T Therapy Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.
To access the data contained in this document please email contactus@visiongain.com
Buy our report today CAR-T Therapy Market Report 2024-2034: Forecasts by Indication (Diffuse Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukaemia (ALL), Follicular Lymphoma, Multiple Myeloma (MM), Others), by Type (Abecma, Yescarta, Kymriah, Tecartus, Others), by Target Antigens (CD19/CD22, BCMA, Others), by Patient (Children, Adults, Seniors), by End-users (Hospitals, Specialty Clinics, Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies. Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: contactus@visiongain.com
1 Report Overview
1.1 Objectives of the Study
1.2 Introduction to CAR-T Therapy Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report for?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2 Executive Summary
3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.3 Impact Analysis
3.3.1 Market Driving Factors
3.3.1.1 Increasing Cancer Incidence
3.3.1.2 Increasing Research and Development to Enhance Treatment with CAR-T Cell Therapy
3.3.1.3 Growing Ongoing Clinical Trials and Regulatory Approvals
3.3.2 Market Restraining Factors
3.3.2.1 High Cost of CAR-T Cell Therapy
3.3.2.2 Safety Concerns Remain a Critical Aspect Influencing the CAR-T Cell Therapy
3.3.3 Market Opportunities
3.3.3.1 Expanding Target Indications
3.3.3.2 Increasing Adoption of CAR-T Cell Therapy in Emerging Markets
3.4 Supply Chain Analysis
3.5 Regulatory Framework
3.6 COVID-19 Impact Analysis
3.7 Porter Analysis
3.8 PEST Analysis
3.8.1 Political Factors:
3.8.2 Economic Factors:
3.8.3 Social Factors:
3.8.4 Technological Factors:
4 CAR-T Therapy Market Analysis by Target Antigens
4.1 Key Findings
4.2 Target Antigens Segment: Market Attractiveness Index
4.3 CAR-T Therapy Market Size Estimation and Forecast by Target Antigens
4.4 CD19/CD22
4.4.1 Market Size by Region, 2024-2034 (US$ Million)
4.4.2 Market Share by Region, 2024 & 2034 (%)
4.5 BCMA
4.5.1 Market Size by Region, 2024-2034 (US$ Million)
4.5.2 Market Share by Region, 2024 & 2034 (%)
4.6 Others
4.6.1 Market Size by Region, 2024-2034 (US$ Million)
4.6.2 Market Share by Region, 2024 & 2034 (%)
5 CAR-T Therapy Market Analysis by Type
5.1 Key Findings
5.2 Type Segment: Market Attractiveness Index
5.3 CAR-T Therapy Market Size Estimation and Forecast by Type
5.4 Abecma
5.4.1 Market Size by Region, 2024-2034 (US$ Million)
5.4.2 Market Share by Region, 2024 & 2034 (%)
5.5 Yescarta
5.5.1 Market Size by Region, 2024-2034 (US$ Million)
5.5.2 Market Share by Region, 2024 & 2034 (%)
5.6 Kymriah
5.6.1 Market Size by Region, 2024-2034 (US$ Million)
5.6.2 Market Share by Region, 2024 & 2034 (%)
5.7 Tecartus
5.7.1 Market Size by Region, 2024-2034 (US$ Million)
5.7.2 Market Share by Region, 2024 & 2034 (%)
5.8 Other Types
5.8.1 Market Size by Region, 2024-2034 (US$ Million)
5.8.2 Market Share by Region, 2024 & 2034 (%)
6 CAR-T Therapy Market Analysis by Indication
6.1 Key Findings
6.2 Indication Segment: Market Attractiveness Index
6.3 CAR-T Therapy Market Size Estimation and Forecast by Indication
6.4 Diffuse Large B-Cell Lymphoma (DLBCL)
6.4.1 Market Size by Region, 2024-2034 (US$ Million)
6.4.2 Market Share by Region, 2024 & 2034 (%)
6.5 Acute Lymphoblastic Leukaemia (ALL)
6.5.1 Market Size by Region, 2024-2034 (US$ Million)
6.5.2 Market Share by Region, 2024 & 2034 (%)
6.6 Follicular Lymphoma
6.6.1 Market Size by Region, 2024-2034 (US$ Million)
6.6.2 Market Share by Region, 2024 & 2034 (%)
6.7 Multiple Myeloma (MM)
6.7.1 Market Size by Region, 2024-2034 (US$ Million)
6.7.2 Market Share by Region, 2024 & 2034 (%)
6.8 Other Indication
6.8.1 Market Size by Region, 2024-2034 (US$ Million)
6.8.2 Market Share by Region, 2024 & 2034 (%)
7 CAR-T Therapy Market Analysis by End-users
7.1 Key Findings
7.2 End-users Segment: Market Attractiveness Index
7.3 CAR-T Therapy Market Size Estimation and Forecast by End-users
7.4 Hospitals
7.4.1 Market Size by Region, 2024-2034 (US$ Million)
7.4.2 Market Share by Region, 2024 & 2034 (%)
7.5 Specialty Clinics
7.5.1 Market Size by Region, 2024-2034 (US$ Million)
7.5.2 Market Share by Region, 2024 & 2034 (%)
7.6 Other End-users
7.6.1 Market Size by Region, 2024-2034 (US$ Million)
7.6.2 Market Share by Region, 2024 & 2034 (%)
8 CAR-T Therapy Market Analysis by Patient
8.1 Key Findings
8.2 Patient Segment: Market Attractiveness Index
8.3 CAR-T Therapy Market Size Estimation and Forecast by Patient
8.4 Children
8.4.1 Market Size by Region, 2024-2034 (US$ Million)
8.4.2 Market Share by Region, 2024 & 2034 (%)
8.5 Adults
8.5.1 Market Size by Region, 2024-2034 (US$ Million)
8.5.2 Market Share by Region, 2024 & 2034 (%)
8.6 Seniors
8.6.1 Market Size by Region, 2024-2034 (US$ Million)
8.6.2 Market Share by Region, 2024 & 2034 (%)
9 CAR-T Therapy Market Analysis by Region
9.1 Key Findings
9.2 Regional Market Size Estimation and Forecast
10 North America CAR-T Therapy Market Analysis
10.1 Key Findings
10.2 North America CAR-T Therapy Market Attractiveness Index
10.3 North America CAR-T Therapy Market by Country, 2024, 2029 & 2034 (US$ Million)
10.4 North America CAR-T Therapy Market Size Estimation and Forecast by Country
10.5 North America CAR-T Therapy Market Size Estimation and Forecast by Target Antigens
10.6 North America CAR-T Therapy Market Size Estimation and Forecast by Type
10.7 North America CAR-T Therapy Market Size Estimation and Forecast by Indication
10.8 North America CAR-T Therapy Market Size Estimation and Forecast by End-users
10.9 North America CAR-T Therapy Market Size Estimation and Forecast by Patients
10.10 U.S. CAR-T Therapy Market Analysis
10.11 Canada CAR-T Therapy Market Analysis
11 Europe CAR-T Therapy Market Analysis
11.1 Key Findings
11.2 Europe CAR-T Therapy Market Attractiveness Index
11.3 Europe CAR-T Therapy Market by Country, 2024, 2029 & 2034 (US$ Million)
11.4 Europe CAR-T Therapy Market Size Estimation and Forecast by Country
11.5 Europe CAR-T Therapy Market Size Estimation and Forecast by Target Antigens
11.6 Europe CAR-T Therapy Market Size Estimation and Forecast by Type
11.7 Europe CAR-T Therapy Market Size Estimation and Forecast by Indication
11.8 Europe CAR-T Therapy Market Size Estimation and Forecast by End-users
11.9 Europe CAR-T Therapy Market Size Estimation and Forecast by Patients
11.10 Germany CAR-T Therapy Market Analysis
11.11 UK CAR-T Therapy Market Analysis
11.12 France CAR-T Therapy Market Analysis
11.13 Italy CAR-T Therapy Market Analysis
11.14 Spain CAR-T Therapy Market Analysis
11.15 Rest of Europe CAR-T Therapy Market Analysis
12 Asia Pacific CAR-T Therapy Market Analysis
12.1 Key Findings
12.2 Asia Pacific CAR-T Therapy Market Attractiveness Index
12.3 Asia Pacific CAR-T Therapy Market by Country, 2024, 2029 & 2034 (US$ Million)
12.4 Asia Pacific CAR-T Therapy Market Size Estimation and Forecast by Country
12.5 Asia Pacific CAR-T Therapy Market Size Estimation and Forecast by Target Antigens
12.6 Asia Pacific CAR-T Therapy Market Size Estimation and Forecast by Type
12.7 Asia Pacific CAR-T Therapy Market Size Estimation and Forecast by Indication
12.8 Asia Pacific CAR-T Therapy Market Size Estimation and Forecast by End-users
12.9 Asia Pacific CAR-T Therapy Market Size Estimation and Forecast by Patients
12.10 China CAR-T Therapy Market Analysis
12.11 Japan CAR-T Therapy Market Analysis
12.12 Singapore CAR-T Therapy Market Analysis
12.13 Australia CAR-T Therapy Market Analysis
12.14 South Korea CAR-T Therapy Market Analysis
12.15 Rest of Asia Pacific CAR-T Therapy Market Analysis
13 Latin America CAR-T Therapy Market Analysis
13.1 Key Findings
13.2 Latin America CAR-T Therapy Market Attractiveness Index
13.3 Latin America CAR-T Therapy Market by Country, 2024, 2029 & 2034 (US$ Million)
13.4 Latin America CAR-T Therapy Market Size Estimation and Forecast by Country
13.5 Latin America CAR-T Therapy Market Size Estimation and Forecast by Target Antigens
13.6 Latin America CAR-T Therapy Market Size Estimation and Forecast by Type
13.7 Latin America CAR-T Therapy Market Size Estimation and Forecast by Indication
13.8 Latin America CAR-T Therapy Market Size Estimation and Forecast by End-users
13.9 Latin America CAR-T Therapy Market Size Estimation and Forecast by Patients
13.10 Brazil CAR-T Therapy Market Analysis
13.11 Mexico CAR-T Therapy Market Analysis
13.12 Rest of Latin America CAR-T Therapy Market Analysis
14 MEA CAR-T Therapy Market Analysis
14.1 Key Findings
14.2 MEA CAR-T Therapy Market Attractiveness Index
14.3 MEA CAR-T Therapy Market by Country, 2024, 2029 & 2034 (US$ Million)
14.4 MEA CAR-T Therapy Market Size Estimation and Forecast by Country
14.5 MEA CAR-T Therapy Market Size Estimation and Forecast by Target Antigens
14.6 MEA CAR-T Therapy Market Size Estimation and Forecast by Type
14.7 MEA CAR-T Therapy Market Size Estimation and Forecast by Indication
14.8 MEA CAR-T Therapy Market Size Estimation and Forecast by End-users
14.9 MEA CAR-T Therapy Market Size Estimation and Forecast by Patients
14.10 Israel CAR-T Therapy Market Analysis
14.11 GCC CAR-T Therapy Market Analysis
14.12 Rest of MEA CAR-T Therapy Market Analysis
15 Company Profiles
15.1 Competitive Landscape, 2023
15.2 Pipeline analysis
15.3 Strategic Outlook
15.4 Gilead Sciences Inc.
15.4.1 Company Snapshot
15.4.2 Company Overview
15.4.3 Financial Analysis
15.4.3.1 Net Revenue, 2018-2023
15.4.3.2 R&D, 2018-2023
15.4.3.3 Regional Market Shares, 2023
15.4.4 Product Benchmarking
15.4.5 Strategic Outlook
15.4.6 SWOT Analysis
15.5 Novartis AG
15.5.1 Company Snapshot
15.5.2 Company Overview
15.5.3 Financial Analysis
15.5.3.1 Net Revenue, 2018-2023
15.5.3.2 R&D, 2018-2023
15.5.3.3 Regional Market Shares, 2023
15.5.4 Product Benchmarking
15.5.5 Strategic Outlook
15.5.6 SWOT Analysis
15.6 Bristol Myers Squibb
15.6.1 Company Snapshot
15.6.2 Company Overview
15.6.3 Financial Analysis
15.6.3.1 Net Revenue, 2018-2023
15.6.3.2 R&D, 2018-2023
15.6.3.3 Regional Market Shares, 2023
15.6.4 Product Benchmarking
15.6.5 Strategic Outlook
15.6.6 SWOT Analysis
15.7 Johnson & Johnson Services, Inc.
15.7.1 Company Snapshot
15.7.2 Company Overview
15.7.3 Financial Analysis
15.7.3.1 Net Revenue, 2017-2022
15.7.3.2 R&D, 2017-2022
15.7.3.3 Regional Market Shares, 2022
15.7.4 Product Benchmarking
15.7.5 SWOT Analysis
15.8 AbbVie Inc.
15.8.1 Company Snapshot
15.8.2 Company Overview
15.8.3 Financial Analysis
15.8.3.1 Net Revenue, 2018-2023
15.8.3.2 R&D, 2018-2023
15.8.3.3 Regional Market Shares, 2023
15.8.4 Product Benchmarking
15.8.5 Strategic Outlook
15.9 Amgen Inc.
15.9.1 Company Snapshot
15.9.2 Company Overview
15.9.3 Financial Analysis
15.9.3.1 Net Revenue, 2018-2023
15.9.3.2 R&D, 2018-2023
15.9.3.3 Regional Market Shares, 2023
15.9.4 Product Benchmarking
15.10 BioNTech S.E.
15.10.1 Company Snapshot
15.10.2 Company Overview
15.10.3 Financial Analysis
15.10.3.1 Net Revenue, 2018-2023
15.10.3.2 R&D, 2018-2023
15.10.4 Product Benchmarking
15.11 Bluebird bio, Inc.
15.11.1 Company Snapshot
15.11.2 Company Overview
15.11.3 Financial Analysis
15.11.3.1 Net Revenue, 2017-2022
15.11.3.2 R&D, 2017-2022
15.11.4 Product Benchmarking
15.12 Caribou Biosciences Inc.
15.12.1 Company Snapshot
15.12.2 Company Overview
15.12.3 Financial Analysis
15.12.3.1 Net Revenue, 2019-2023
15.12.3.2 R&D, 2019-2023
15.12.4 Product Benchmarking
15.12.5 Strategic Outlook
15.13 GSK plc
15.13.1 Company Snapshot
15.13.2 Company Overview
15.13.3 Financial Analysis
15.13.3.1 Net Revenue, 2018-2023
15.13.3.2 R&D, 2018-2023
15.13.3.3 Regional Market Shares, 2023
15.13.4 Product Benchmarking
15.14 CARsgen Therapeutics Holdings Limited
15.14.1 Company Snapshot
15.14.2 Company Overview
15.14.3 Pipeline Product Benchmarking
15.14.4 Strategic Outlook
15.15 Pfizer Inc.
15.15.1 Company Snapshot
15.15.2 Company Overview
15.15.3 Financial Analysis
15.15.3.1 Net Revenue, 2018-2023
15.15.3.2 R&D, 2018-2023
15.15.3.3 Regional Market Shares, 2023
15.15.4 Pipeline Product Benchmarking
15.15.5 Strategic Outlook
15.16 Autolus Therapeutics
15.16.1 Company Snapshot
15.16.2 Company Overview
15.16.3 Pipeline Product Benchmarking
15.16.4 Strategic Outlook
15.17 Intellia Therapeutics
15.17.1 Company Snapshot
15.17.2 Company Overview
15.17.3 Pipeline Product Benchmarking
15.17.4 Strategic Outlook
15.18 2seventy bio, Inc.
15.18.1 Company Snapshot
15.18.2 Company Overview
15.18.3 Pipeline Product Benchmarking
15.18.4 Strategic Outlook
16 Conclusion and Recommendations
16.1 Concluding Remarks from Visiongain
16.2 Recommendations for Market Players
List of Tables
Table 1 CAR-T Therapy Market Snapshot, 2024 & 2034 (US$ Million, AGR %)
Table 2 Companion Diagnostic Market Forecast by Target Antigens, 2024-2034 (US$ Million, CAGR %, AGR %)
Table 3 CD19/CD22 Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 4 BCMA Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 5 Others Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 6 Companion Diagnostic Market Forecast by Type, 2024-2034 (US$ Million, CAGR %, AGR %)
Table 7 Abecma Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 8 Yescarta Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 9 Kymriah Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 10 Tecartus Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 11 Other Types Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 12 Companion Diagnostic Market Forecast by Indication, 2024-2034 (US$ Million, CAGR %, AGR %)
Table 13 Diffuse Large B-Cell Lymphoma (DLBCL) Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 14 Acute Lymphoblastic Leukaemia (ALL) Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 15 Follicular Lymphoma Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 16 Multiple Myeloma (MM) Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 17 Other Indication Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 18 CAR-T Therapy Market Forecast by End-users, 2024-2034 (US$ Million, CAGR %, AGR %)
Table 19 Hospitals Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 20 Specialty Clinics Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 21 Other End-users Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 22 CAR-T Therapy Market Forecast by Patient, 2024-2034 (US$ Million, CAGR %, AGR %)
Table 23 Children Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 24 Adults Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 25 Seniors Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 26 CAR-T Therapy Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 27 North America CAR-T Therapy Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Table 28 North America CAR-T Therapy Market Forecast by Target Antigens, 2024-2034 (US$ Million, AGR %)
Table 29 North America CAR-T Therapy Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Table 30 North America CAR-T Therapy Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
Table 31 North America CAR-T Therapy Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
Table 32 North America CAR-T Therapy Market Forecast by Patients, 2024-2034 (US$ Million, AGR %)
Table 33 U.S. CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 34 Canada CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 35 Europe CAR-T Therapy Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Table 36 Europe CAR-T Therapy Market Forecast by Target Antigens, 2024-2034 (US$ Million, AGR %)
Table 37 Europe CAR-T Therapy Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Table 38 Europe CAR-T Therapy Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
Table 39 Europe CAR-T Therapy Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
Table 40 Europe CAR-T Therapy Market Forecast by Patients, 2024-2034 (US$ Million, AGR %)
Table 41 Germany CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 42 UK CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 43 France CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 44 Italy CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 45 Spain CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 46 Rest of Europe CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 47 Asia Pacific CAR-T Therapy Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Table 48 Asia Pacific CAR-T Therapy Market Forecast by Target Antigens, 2024-2034 (US$ Million, AGR %)
Table 49 Asia Pacific CAR-T Therapy Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Table 50 Asia Pacific CAR-T Therapy Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
Table 51 Asia Pacific CAR-T Therapy Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
Table 52 Asia Pacific CAR-T Therapy Market Forecast by Patients, 2024-2034 (US$ Million, AGR %)
Table 53 China CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 54 Japan CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 55 Singapore CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 56 Australia CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 57 South Korea CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 58 Rest of Asia Pacific CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 59 Latin America CAR-T Therapy Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Table 60 Latin America CAR-T Therapy Market Forecast by Target Antigens, 2024-2034 (US$ Million, AGR %)
Table 61 Latin America CAR-T Therapy Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Table 62 Latin America CAR-T Therapy Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
Table 63 Latin America CAR-T Therapy Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
Table 64 Latin America CAR-T Therapy Market Forecast by Patients, 2024-2034 (US$ Million, AGR %)
Table 65 Brazil CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 66 Mexico CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 67 Rest of Latin America CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 68 MEA CAR-T Therapy Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Table 69 MEA CAR-T Therapy Market Forecast by Target Antigens, 2024-2034 (US$ Million, AGR %)
Table 70 MEA CAR-T Therapy Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Table 71 MEA CAR-T Therapy Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
Table 72 MEA CAR-T Therapy Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
Table 73 MEA CAR-T Therapy Market Forecast by Patients, 2024-2034 (US$ Million, AGR %)
Table 74 Israel CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 75 GCC CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 76 Rest of MEA CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 77 Strategic Outlook
Table 78 Gilead Sciences Inc.: Key Details (CEO, H.Q., Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 79 Gilead Sciences Inc.: Product Benchmarking
Table 80 Gilead Sciences Inc.: Strategic Outlook
Table 81 Novartis AG: Key Details (CEO, H.Q., Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 82 Novartis AG: Product Benchmarking
Table 83 Novartis AG: Strategic Outlook
Table 84 Bristol Myers Squibb: Key Details (CEO, H.Q., Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 85 Bristol Myers Squibb: Product Benchmarking
Table 86 Bristol Myers Squibb: Strategic Outlook
Table 87 Johnson & Johnson Services, Inc.: Key Details (CEO, H.Q., Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 88 Johnson & Johnson Services, Inc.: Product Benchmarking
Table 89 AbbVie Inc.: Key Details (CEO, H.Q., Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 90 AbbVie Inc.: Product Benchmarking
Table 91 AbbVie Inc.: Strategic Outlook
Table 92 Amgen Inc.: Key Details (CEO, H.Q., Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 93 Amgen Inc.: Product Benchmarking
Table 94 BioNTech S.E.: Key Details (CEO, H.Q., Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 95 BioNTech SE: Product Benchmarking
Table 96 Bluebird bio, Inc.: Key Details (CEO, H.Q., Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 97 Bluebird bio, Inc..: Product Benchmarking
Table 98 Caribou Biosciences Inc.: Key Details (CEO, H.Q., Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 99 Caribou Biosciences Inc.: Product Benchmarking
Table 100 Caribou Biosciences Inc.: Strategic Outlook
Table 101 GSK plc: Key Details (CEO, H.Q., Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 102 GSK plc: Product Benchmarking
Table 103 CARsgen Therapeutics Holdings Limited: Key Details (CEO, H.Q., Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 104 CARsgen Therapeutics Holdings Limited: Product Benchmarking
Table 105 CARsgen Therapeutics Holdings Limited: Strategic Outlook
Table 106 Pfizer Inc.: Key Details (CEO, H.Q., Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 107 Pfizer Inc.: Product Benchmarking
Table 108 Pfizer Inc.: Strategic Outlook
Table 109 Autolus Therapeutics: Key Details (CEO, H.Q., Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 110 Autolus Therapeutics: Product Benchmarking
Table 111 Autolus Therapeutics: Strategic Outlook
Table 112 Intellia Therapeutics: Key Details (CEO, H.Q., Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 113 Intellia Therapeutics: Product Benchmarking
Table 114 Intellia Therapeutics: Strategic Outlook
Table 115 2seventy bio, Inc.: Key Details (CEO, H.Q., Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 116 2seventy bio, Inc.: Product Benchmarking
Table 117 2seventy bio, Inc.: Strategic Outlook
List of Figures
Figure 1 CAR-T Therapy Market Segmentation
Figure 2 CAR-T Therapy Market by Target Antigens: Market Attractiveness Index
Figure 3 CAR-T Therapy Market by Type: Market Attractiveness Index
Figure 4 CAR-T Therapy Market by Indication: Market Attractiveness Index
Figure 5 CAR-T Therapy Market by End-users: Market Attractiveness Index
Figure 6 CAR-T Therapy Market by Patient: Market Attractiveness Index
Figure 7 CAR-T Therapy Market Attractiveness Index by Region
Figure 8 CAR-T Therapy Market: Market Dynamics
Figure 9 CAR-T Therapy Market: Impact Analysis
Figure 10 CAR-T Therapy: Supply Chain Analysis
Figure 11 PEST Analysis of the CAR-T Therapy Market
Figure 12 CAR-T Therapy Market by Target Antigens: Market Attractiveness Index
Figure 13 CAR-T Therapy Market Forecast by Target Antigens, 2024-2034 (US$ Million, AGR %)
Figure 14 CAR-T Therapy Market Share Forecast by Target Antigens, 2024, 2029, 2034 (%)
Figure 15 CD19/CD22 Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 16 CD19/CD22 Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 17 BCMA Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 18 BCMA Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 19 Others Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 20 Others Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 21 CAR-T Therapy Market by Type: Market Attractiveness Index
Figure 22 CAR-T Therapy Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 23 CAR-T Therapy Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 24 Abecma Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 25 Abecma Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 26 Yescarta Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 27 Yescarta Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 28 Kymriah Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 29 Kymriah Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 30 Tecartus Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 31 Tecartus Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 32 Other Types Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 33 Other Types Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 34 Companion Diagnostics Market by Indication: Market Attractiveness Index
Figure 35 CAR-T Therapy Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
Figure 36 Companion Diagnostics Market Share Forecast by Indication, 2024, 2029, 2034 (%)
Figure 37 Diffuse Large B-Cell Lymphoma (DLBCL) Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 38 Diffuse Large B-Cell Lymphoma (DLBCL) Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 39 Acute Lymphoblastic Leukaemia (ALL) Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 40 Acute Lymphoblastic Leukaemia (ALL) Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 41 Follicular Lymphoma Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 42 Follicular Lymphoma Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 43 Multiple Myeloma (MM) Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 44 Multiple Myeloma (MM) Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 45 Other Indication Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 46 Other Indication Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 47 CAR-T Therapy Market by End-users: Market Attractiveness Index
Figure 48 CAR-T Therapy Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
Figure 49 CAR-T Therapy Market Share Forecast by End-users, 2024, 2029, 2034 (%)
Figure 50 Hospitals Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 51 Hospitals Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 52 Specialty Clinics Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 53 Specialty Clinics Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 54 Other End-users Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 55 Other End-users Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 56 CAR-T Therapy Market by Patient: Market Attractiveness Index
Figure 57 CAR-T Therapy Market Forecast by Patient, 2024-2034 (US$ Million, AGR %)
Figure 58 CAR-T Therapy Market Share Forecast by Patient, 2024, 2029, 2034 (%)
Figure 59 Children Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 60 Children Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 61 Adults Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 62 Adults Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 63 Seniors Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 64 Seniors Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 65 CAR-T Therapy Market Forecast by Region 2024 and 2034 (Revenue, CAGR%)
Figure 66 CAR-T Therapy Market Share Forecast by Region 2024, 2029, 2034 (%)
Figure 67 CAR-T Therapy Market by Region, 2024-2034 (US$ Million, AGR %)
Figure 68 North America CAR-T Therapy Market Attractiveness Index
Figure 69 North America CAR-T Therapy Market by Region, 2024, 2029 & 2034 (US$ Million)
Figure 70 North America CAR-T Therapy Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 71 North America CAR-T Therapy Market Share Forecast by Country, 2024 & 2034 (%)
Figure 72 North America CAR-T Therapy Market Forecast by Target Antigens, 2024-2034 (US$ Million, AGR %)
Figure 73 North America CAR-T Therapy Market Share Forecast by Target Antigens, 2024 & 2034 (%)
Figure 74 North America CAR-T Therapy Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 75 North America CAR-T Therapy Market Share Forecast by Type, 2024 & 2034 (%)
Figure 76 North America CAR-T Therapy Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
Figure 77 North America CAR-T Therapy Market Share Forecast by Indication, 2024 & 2034 (%)
Figure 78 North America CAR-T Therapy Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
Figure 79 North America CAR-T Therapy Market Share Forecast by End-users, 2024 & 2034 (%)
Figure 80 North America CAR-T Therapy Market Forecast by Patients, 2024-2034 (US$ Million, AGR %)
Figure 81 North America CAR-T Therapy Market Share Forecast by Patients, 2024 & 2034 (%)
Figure 82 U.S. CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 83 Canada CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 84 Europe CAR-T Therapy Market Attractiveness Index
Figure 85 Europe CAR-T Therapy Market by Region, 2024, 2029 & 2034 (US$ Million)
Figure 86 Europe CAR-T Therapy Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 87 Europe CAR-T Therapy Market Share Forecast by Country, 2024 & 2034 (%)
Figure 88 Europe CAR-T Therapy Market Forecast by Target Antigens, 2024-2034 (US$ Million, AGR %)
Figure 89 Europe CAR-T Therapy Market Share Forecast by Target Antigens, 2024 & 2034 (%)
Figure 90 Europe CAR-T Therapy Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 91 Europe CAR-T Therapy Market Share Forecast by Type, 2024 & 2034 (%)
Figure 92 Europe CAR-T Therapy Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
Figure 93 Europe CAR-T Therapy Market Share Forecast by Indication, 2024 & 2034 (%)
Figure 94 Europe CAR-T Therapy Market Forecast by End-user, 2024-2034 (US$ Million, AGR %)
Figure 95 Europe CAR-T Therapy Market Share Forecast by End-user, 2024 & 2034 (%)
Figure 96 Europe CAR-T Therapy Market Forecast by Patients, 2024-2034 (US$ Million, AGR %)
Figure 97 Europe CAR-T Therapy Market Share Forecast by Patients, 2024 & 2034 (%)
Figure 98 Germany CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 99 UK CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 100 France CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 101 Italy CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 102 Spain CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 103 Rest of Europe CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 104 Asia Pacific CAR-T Therapy Market Attractiveness Index
Figure 105 Asia Pacific CAR-T Therapy Market by Region, 2024, 2029 & 2034 (US$ Million)
Figure 106 Asia Pacific CAR-T Therapy Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 107 Asia Pacific CAR-T Therapy Market Share Forecast by Country, 2024 & 2034 (%)
Figure 108 Asia Pacific CAR-T Therapy Market Forecast by Target Antigens, 2024-2034 (US$ Million, AGR %)
Figure 109 Asia Pacific CAR-T Therapy Market Share Forecast by Target Antigens, 2024 & 2034 (%)
Figure 110 Asia Pacific CAR-T Therapy Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 111 Asia Pacific CAR-T Therapy Market Share Forecast by Type, 2024 & 2034 (%)
Figure 112 Asia Pacific CAR-T Therapy Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
Figure 113 Asia Pacific CAR-T Therapy Market Share Forecast by Indication, 2024 & 2034 (%)
Figure 114 Asia Pacific CAR-T Therapy Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
Figure 115 Asia Pacific CAR-T Therapy Market Share Forecast by End-users, 2024 & 2034 (%)
Figure 116 Asia Pacific CAR-T Therapy Market Forecast by Patients, 2024-2034 (US$ Million, AGR %)
Figure 117 Asia Pacific CAR-T Therapy Market Share Forecast by Patients, 2024 & 2034 (%)
Figure 118 China CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 119 Japan CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 120 Singapore CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 121 Australia CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 122 South Korea CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 123 Rest of Asia Pacific CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 124 Latin America CAR-T Therapy Market Attractiveness Index
Figure 125 Latin America CAR-T Therapy Market by Region, 2024, 2029 & 2034 (US$ Million)
Figure 126 Latin America CAR-T Therapy Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 127 Latin America CAR-T Therapy Market Share Forecast by Country, 2024 & 2034 (%)
Figure 128 Latin America CAR-T Therapy Market Forecast by Target Antigens, 2024-2034 (US$ Million, AGR %)
Figure 129 Latin America CAR-T Therapy Market Share Forecast by Target Antigens, 2024 & 2034 (%)
Figure 130 Latin America CAR-T Therapy Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 131 Latin America CAR-T Therapy Market Share Forecast by Type, 2024 & 2034 (%)
Figure 132 Latin America CAR-T Therapy Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
Figure 133 Latin America CAR-T Therapy Market Share Forecast by Indication, 2024 & 2034 (%)
Figure 134 Latin America CAR-T Therapy Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
Figure 135 Latin America CAR-T Therapy Market Share Forecast by End-users, 2024 & 2034 (%)
Figure 136 Latin America CAR-T Therapy Market Forecast by Patients, 2024-2034 (US$ Million, AGR %)
Figure 137 Latin America CAR-T Therapy Market Share Forecast by Patients, 2024 & 2034 (%)
Figure 138 Brazil CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 139 Mexico CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 140 Rest of Latin America CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 141 MEA CAR-T Therapy Market Attractiveness Index
Figure 142 MEA CAR-T Therapy Market by Region, 2024, 2029 & 2034 (US$ Million)
Figure 143 MEA CAR-T Therapy Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 144 MEA CAR-T Therapy Market Share Forecast by Country, 2024 & 2034 (%)
Figure 145 MEA CAR-T Therapy Market Forecast by Target Antigens, 2024-2034 (US$ Million, AGR %)
Figure 146 MEA CAR-T Therapy Market Share Forecast by Target Antigens, 2024 & 2034 (%)
Figure 147 MEA CAR-T Therapy Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 148 MEA CAR-T Therapy Market Share Forecast by Type, 2024 & 2034 (%)
Figure 149 MEA CAR-T Therapy Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
Figure 150 MEA CAR-T Therapy Market Share Forecast by Indication, 2024 & 2034 (%)
Figure 151 MEA CAR-T Therapy Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
Figure 152 MEA CAR-T Therapy Market Share Forecast by End-users, 2024 & 2034 (%)
Figure 153 MEA CAR-T Therapy Market Forecast by Patients, 2024-2034 (US$ Million, AGR %)
Figure 154 Middle East & Africa CAR-T Therapy Market Share Forecast by Patients, 2024 & 2034 (%)
Figure 155 Israel CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 156 GCC CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 157 Rest of MEA CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 158 CAR-T Therapy Market: Company Share/Ranking, 2023
Figure 159 Gilead Sciences Inc.: Net Revenue, 2018-2023 (US$ Million, AGR%)
Figure 160 Gilead Sciences Inc.: R&D, 2018-2023 (US$ Million, AGR%)
Figure 161 Gilead Sciences Inc.: Regional Market Shares, 2023
Figure 162 Gilead Sciences Inc.: SWOT Analysis
Figure 163 Novartis AG: Net Revenue, 2018-2023 (US$ Million, AGR%)
Figure 164 Novartis AG: R&D, 2018-2023 (US$ Million, AGR%)
Figure 165 Novartis AG: Regional Market Shares, 2023
Figure 166 Novartis AG: SWOT Analysis
Figure 167 Bristol Myers Squibb: Net Revenue, 2018-2023 (US$ Million, AGR%)
Figure 168 Bristol Myers Squibb: R&D, 20180-2023 (US$ Million, AGR%)
Figure 169 Bristol Myers Squibb: Regional Market Shares, 2023
Figure 170 Bristol Myers Squibb: SWOT Analysis
Figure 171 Johnson & Johnson (J&J): Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 172 Johnson & Johnson (J&J): R&D, 2017-2022 (US$ Million, AGR%)
Figure 173 Johnson & Johnson (J&J): Regional Market Shares, 2022
Figure 174 Johnson & Johnson Services, Inc.: SWOT Analysis
Figure 175 AbbVie Inc.: Net Revenue, 2018-2023 (US$ Million, AGR%)
Figure 176 AbbVie Inc.: R&D, 2018-2023 (US$ Million, AGR%)
Figure 177 AbbVie Inc.: Regional Market Shares, 2023
Figure 178 Amgen Inc.: Net Revenue, 2018-2023 (US$ Million, AGR%)
Figure 179 Amgen Inc.: R&D, 2018-2023 (US$ Million, AGR%)
Figure 180 Amgen Inc.: Regional Market Shares, 2023
Figure 181 BioNTech S.E.: Net Revenue, 2018-2023 (US$ Million, AGR%)
Figure 182 BioNTech S.E.: R&D, 2018-2023 (US$ Million, AGR%)
Figure 183 Bluebird bio, Inc.: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 184 Bluebird bio, Inc.: R&D, 2017-2022 (US$ Million, AGR%)
Figure 185 Caribou Biosciences, Inc.: Net Revenue, 2019-2023 (US$ Million, AGR%)
Figure 186 Caribou Biosciences, Inc.: R&D, 2019-2023 (US$ Million, AGR%)
Figure 187 GSK plc: Net Revenue, 2018-2023 (US$ Million, AGR%)
Figure 188 GSK plc: R&D, 2018-2023 (US$ Million, AGR%)
Figure 189 GSK plc: Regional Market Shares, 2023
Figure 190 Pfizer: Net Revenue, 2018-2023 (US$ Million, AGR%)
Figure 191 Pfizer: R&D, 2018-2023 (US$ Million, AGR%)
Figure 192 Pfizer: Regional Market Shares, 2023
List of Companies Profiled in the Report
2seventy bio, Inc.
AbbVie Inc.
Amgen Inc.
Autolus Therapeutics
BioNTech S.E.
Bluebird bio Inc.
Bristol-Myers Squibb
Caribou Biosciences, Inc.
CARsgen Therapeutics Holdings Limited
Gilead Sciences Inc.
GSK plc
Intellia Therapeutics
Johnson & Johnson Services, Inc.
Novartis AG
Pfizer Inc.
List of Other Companies Mentioned in the Report
ABC Biopharma
Amgen Inc.
BeiGene
Cansino Biologics
Carina Biotech
Cellivue Therapeutics
Cellular Biomedicine Group
Century Therapeutics
Chimeric Therapeutics
CytoMed Therapeutics
IndiaBioScience
Janssen
JW Therapeutics
Legend Biotech
Leucid Bio
Nanjing Legend Biotech
NexImmune
Poseida Therapeutics
Precision BioSciences'
Takara Bio
Xyphos Biosciences
List of Associations Mentioned in the Report
Central Drugs Standard Control Organization
China National Medical Products Administration
European Medicines Agency
Japan Pharmaceuticals and Medical Devices Agency
Kyoto University's Institute for Advanced Research
Leukemia & Lymphoma Society (LLS)
Memorial Sloan Kettering Cancer Center
National Medical Products Administration
Research Institutions and Academic Medical Centers
Sarah Cannon Cancer Institute
Singapore's National University Cancer Institute
Swiss Federal Institute of Technology
Therapeutic Goods Administration
University of Maryland School of Medicine
University of Maryland School of Medicine (UMSOM)
University of Texas MD Anderson Cancer Center
U.S. Food and Drug Administration
World Health Organization (WHO)European Medicines Agency (EMA)
